CD123 Is Consistently Expressed on NPM1-Mutated AML Cells

CD34+CD38−CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents

(2020) François Vergez et al.   Cancers

CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions

(2020) Sherly Mardiana et al.   Frontiers in Oncology

NPM1-mutated acute myeloid leukemia: from bench to bedside

(2020) Brunangelo Falini et al.   BLOOD

Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity

(2020) Marlon Arnone et al.   Cancers

CD123 CAR T Cells for the Treatment of Myelodysplastic Syndrome

(2019) Brett M. Stevens et al.   EXPERIMENTAL HEMATOLOGY

IFN-γ and TNF-α aggravate endothelial damage caused by CD123-targeted CAR T cell

(2019) Yao Sun et al.   OncoTargets and Therapy

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies

(2019) Testa et al.   Cancers

Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience

(2018) Chezi Ganzel et al.   AMERICAN JOURNAL OF HEMATOLOGY

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML

(2018) S. Haubner et al.   LEUKEMIA

CARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment

(2018) Clare Y. Slaney et al.   Cancer Discovery

Will CAR T cell therapy have a role in AML? Promises and pitfalls

(2018) Katherine D. Cummins et al.   SEMINARS IN HEMATOLOGY

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3 -internal tandem duplication genotypes

(2018) Prajwal C. Boddu et al.   CANCER

CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping

(2018) Anne E. Bras et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies

(2017) Maria Caterina Rotiroti et al.   HUMAN GENE THERAPY

Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia

(2017) Tomohiro Yabushita et al.   LEUKEMIA & LYMPHOMA

Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia

(2017) Silvia Arcangeli et al.   MOLECULAR THERAPY

On the origin of relapse in AML

(2017) Brian A. Jonas   Science Translational Medicine

CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission

(2017) L H Xie et al.   Blood Cancer Journal

High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia

(2017) Adriana Plesa et al.   World Journal of Stem Cells

Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones

(2016) Adhra Al-Mawali et al.   Journal of Hematology & Oncology

Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2

(2016) Zhuo Ren et al.   Cell Death & Disease

A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia

(2015) D. F. Angelini et al.   CLINICAL CANCER RESEARCH

T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia

(2015) Armen Mardiros et al.   CURRENT OPINION IN HEMATOLOGY

Prognostic Significance ofNPM1Mutations in the Absence ofFLT3–Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report

(2015) Fabiana Ostronoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

(2014) S. Gill et al.   BLOOD

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

(2014) A Ehninger et al.   Blood Cancer Journal

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

(2013) M. Casucci et al.   BLOOD

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor

(2013) Sarah Tettamanti et al.   BRITISH JOURNAL OF HAEMATOLOGY

Incidence, survival and prevalence of myeloid malignancies in Europe

(2012) O. Visser et al.   EUROPEAN JOURNAL OF CANCER

Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia

(2012) S Anguille et al.   LEUKEMIA

High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study

(2011) F. Vergez et al.   HAEMATOLOGICA

CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice

(2010) M. P. Martelli et al.   BLOOD

Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells

(2009) Liqing Jin et al.   Cell Stem Cell

Acute myeloid leukemia stem cells: seek and destroy

(2009) Gail J Roboz et al.   Expert Review of Hematology

A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia

(2008) M P Martelli et al.   LEUKEMIA